Sionna Therapeutics Inc
SION
NASDAQ
Biotechnology
$6.46
USD
-0.08 (-1.22%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.31B
Volume 2.9M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-97.38M
TTM
— YoY
Operating Cash Flow
$-75.92M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 6.5 | 7.8 | 8.4 | 10.6 | 10.6 |
Other Operating Expenses | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 21.7 | 23.8 | 23.6 | 29.6 | 32.5 |
Operating Income | -21.7 | -23.8 | -23.6 | -29.6 | -32.5 |
EBITDA | -21.6 | -23.6 | -23.5 | -29.4 | -32.3 |
Other Income / Expense | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 3.7 | 3.5 | 3.2 | 2.8 | 2.6 |
Income Before Income Taxes | -18.1 | -20.3 | -20.4 | -26.8 | -29.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -18.1 | -20.3 | -20.4 | -26.8 | -29.9 |
Consolidated Net Income / Loss | -18.1 | -20.3 | -20.4 | -26.8 | -29.9 |
Net Income Attributable to Common Shareholders | -18.1 | -20.3 | -20.4 | -26.8 | -29.9 |
Basic EPS | -$0.41 | -$0.46 | -$0.46 | -$0.60 | -$0.66 |
Diluted EPS | -$0.41 | -$0.46 | -$0.46 | -$0.60 | -$0.66 |
Basic Shares Outstanding | 44.1M | 44.3M | 44.9M | 44.9M | 45.1M |
Diluted Shares Outstanding | 44.1M | 44.3M | 44.9M | 44.9M | 45.1M |